Subcutaneous Biologics Market Report 2015-2025: Products, Technologies and Delivery Systems

News provided by

Feb 16, 2015, 11:34 ET

DUBLIN, Feb .16, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/q3zb6x/subcutaneous) has announced the addition of the "Subcutaneous Biologics Market, 2015 - 2025" report to their offering.

The Subcutaneous Biologics: Products, Technologies and Delivery Systems' report provides an extensive study of the rapidly growing market of subcutaneous biologic drugs. It is an emerging area that is gaining substantial attention from researchers and manufacturers across the globe. Subcutaneous delivery provides numerous advantages over other routes of delivery. Some of the major benefits include reduction in time spent in drug administration, reduced patient time at healthcare facilities, decreased healthcare costs and improved therapy compliance.The utility of viscous biologics in the treatment of chronic diseases, the increasing trend of self-medication and requirement of high concentration subcutaneous formulation of biologics are some of the driving factors behind the market's evolution.

The study not only provides an in-depth analysis of pipeline and marketed subcutaneous biologic drug candidates but also includes a detailed discussion on the formulation and delivery aspects associated with such biological macromolecules. In addition, the advancing trend of transition from intravenous to subcutaneous and the fundamental challenge of formulation of biologics into subcutaneous format highlight the crucial role of technology developers in this field. The requirement of suitable delivery systems for subcutaneous administration also presents immense growth prospects for device manufacturing firms which are working aggressively to provide a diverse range of self-injection devices.

In fact, one of the key objectives of the report is to identify the future potential of the industry for these stakeholders. In addition to the market forecast for subcutaneous biologic drugs, we have also provided a ten year forecast of the subcutaneous delivery systems including prefilled syringes, drug reconstitution systems and bolus injectors. The base year for the report is 2014. The research, analysis and insights presented in this report is backed by a deep understanding of key insights gathered both from primary and secondary research.

Highlights:

Pharmaceutical giants,such as Roche,are involved in development of subcutaneous formulations for their approved therapies in order to enhance their use and adoption. Herceptin SC and MabThera SC represent some of the successful examples of this novel approach.
With formulation being a crucial aspect, technology developers have carved an important role for themselves in the market. During our research, we identified nine such companies which are involved in development and commercialization of technologies to form stable subcutaneous formulations of proteins, peptides, antibodies and other large molecules. Halozyme is a pertinent example; the company has entered into numerous deals with big pharmaceutical firms to develop subcutaneous formulations for their products.
The pipeline of subcutaneous biologics represents one of the underlying drivers of the market. In addition to the 55 marketed subcutaneous biologics, there are 196other such molecules in clinical development. Though biologics are being developed targeting numerous diseases across the therapeutic spectrum, inflammatory and metabolic disorders are amongst the prime focus areas.
We expect the overall market of subcutaneous biologics to grow at a CAGR of 7.0% over the next decade; factors such as the advantages of subcutaneous administration and the growing trend for self-injection medications will drive this uptake.
In terms of delivery systems, we expect the annual market for prefilled syringes, novel drug reconstitution systems and bolus injectors for subcutaneous administration of biologics to be worth USD 1.4 billion, USD 0.9 billion and USD 8.1 billion respectively by 2025.
The technology developers stand to benefit from technology licensing deals; these generally present strong financial incentives to the licensors in the form of upfront payments (USD 8 - 20 million) and milestone payments (USD 100 - 300 million).

Key Topics Covered:

1. Preface

2. Executive Summary

3. Introduction

4. Subcutaneous Biologics Market

5. Technologies For Subcutaneous Formulation Of Biologics

6. Drug Delivery Systems For Subcutaneous Delivery Of Biologics

7. Market Sizing And Forecast

8. Case Studies: Technology Developers

9. Swot Analysis

10. Interview Transcripts

11. Conclusion

12 Appendix 1: Tabulated Data

13 Appendix 2: List Of Companies

Companies Mentioned

- Abbott Laboratories
- Activa
- Adamis Pharmaceuticals Corporation
- ADOCIA
- Advantage Health Services
- Aguettant
- Ajinomoto Althea Inc.
- Alnylam Pharmaceuticals
- Amgen
- Antares Pharma
- Aptar Pharm
- Aradigm Corporation
- Arte Corporation
- Ascendis Pharma
- AstraZeneca
- Bang and Olufsen
- Battelle
- Baxter
- Bayer
- Becton Dickinson
- Bespak
- Biogen Idec
- Bioject Medical Technologies, Inc.
- Bristol-Myers Squibb Co
- Calibra Medical
- CeQur SA
- Chengdu Instituteof Biologic Products, Biogenetech
- CNS Therapeutics (acquired by Mallinckrodt)
- CSL Behring
- Duoject
- Eagle Pharmaceuticals
- Elcam Medical
- Eli Lilly
- EMD Serono
- Emergent Biosolutions
- Enable Injections
- Eternity Healthcare
- Evans enterprise
- Flamel Technologies
- Future injection technologies
- Genzyme
- Gerresheimer
- Grifols Therapeutics (acquired Talecris Biotherapeutics)
- GSK
- Halozyme
- Haselmeier
- Health-Mor
- Injex - Equidyne Systems
- Integrity Bio
- Janssen Biotech, Inc.
- Kaleo Inc.
- Mediject
- MedinCell
- MedPro
- Merck
- Meridian
- National Medical Products, Inc.
- Nipro (acquired MGlas AG)
- NouvaOmpi
- Novartis
- Novo Nordisk
- Owen Mumford
- PA Consulting
- Penjet corporation
- Pfizer
- Plas-Tech Engineering
- Ratio Inc.
- Roche
- Roselabs Bioscience
- Sanofi
- Scandinavian Health Limited (SHL Medical)
- Schering Corporation (Merck Serono)
- Schott
- Sensile Medical
- Shandong Weigao
- Sobi
- SteadyMed
- Taisei Kako
- Tekmira
- Terumo Corporation
- The Medical House
- UCB
- Unilife Corporation
- United Therapeutics
- Valeritas
- Vetter Pharma
- West Pharmaceutical Solutions
- Xeris Pharmaceuticals
- Ypsomed

For more information visit http://www.researchandmarkets.com/research/q3zb6x/subcutaneous